South Korean biopharmaceutical firm Celltrion (Kosdaq: 068270) and its partner Pfizer (NYSE: PFE) have presented the primary outcome from its pivotal randomized controlled trial of CT-P13, a Remicade (infliximab) biosimilar which is branded as Remsima and Inflectra, in Crohn’s diseasez
These data, presented at the Congress of the European Crohn’s and Colitis Organization (ECCO), indicates that the safety and efficacy of CT-P13 in patients with moderate-to-severe Crohn’s disease (CD) is comparable to those treated with Remicade, the blockbuster drug from US health care giant Johnson & Johnson (NYSE: JNJ).
"Gastroenterologists have for some time wanted the reassurance of a randomized controlled trial"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze